Sun Pharma Advanced Research Company Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sun Pharma Advanced Research Company Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-125 of operating cash. Lower than 97% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 2 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-125Over the last 3 years, every ₹100 of reported profit came with ₹-125 of operating cash.
Lower than 97% of Healthcare companies in India.
Self-Funding Ratio
-16.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in India.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 84%
Sales fell 84% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-84% / +162%In 3 years sales changed by -84% while total assets changed by +162%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-0.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in India.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in India.
Tangible Assets Ratio
97%Of every ₹100 the company owns, ₹97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Healthcare companies in India.
Tangible Net Worth Ratio
95%Of every ₹100 of net worth, ₹95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 52% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Sun Pharma Advanced Research Company Limited owes ₹0.38 for every ₹1 it owns. Sun Pharma Advanced Research Company Limited returned to profit in the year to Mar 2026, after a loss the year before.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
3.5Investors pay ₹3.5 for every ₹1 of Sun Pharma Advanced Research Company Limited's yearly profit, lower than almost all Healthcare companies in India.
P/B ratio
4.20The share price is 4.20 times Sun Pharma Advanced Research Company Limited's book value per share, lower than 57% of Healthcare companies in India.
Market cap
₹5,617 CrThe total market value of all of Sun Pharma Advanced Research Company Limited's shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,339 CrWhat Sun Pharma Advanced Research Company Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹41.26Net worth divided by the number of shares. The share price of ₹173.09 is 4.2 times this, which is the P/B above.
Return on equity (ROE)
118.3%Sun Pharma Advanced Research Company Limited earned 118.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in India.
Owes vs Owns
0.38×Sun Pharma Advanced Research Company Limited owes ₹0.38 for every ₹1 it owns (low), higher than 53% of Healthcare companies in India.
Dividend yield
NoneSun Pharma Advanced Research Company Limited does not currently pay a dividend.
Revenue growth
-45%Revenue fell 45% in the year to Mar 2026, and shrank 45% a year on average over 3 years.
Profit growth
Back to profitSun Pharma Advanced Research Company Limited returned to profit in the year to Mar 2026, after a loss the year before.
Profit margin
3967.5%Sun Pharma Advanced Research Company Limited keeps ₹3967 of every ₹100 of revenue as net profit.
Cash quality
-0.2×Cash from Sun Pharma Advanced Research Company Limited's business was -0.2× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
50.6×Sun Pharma Advanced Research Company Limited's operating profit covered its interest costs 50.6 times in the year to Mar 2026.
Cash vs debt
Net debtSun Pharma Advanced Research Company Limited had ₹557 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Sun Pharma Advanced Research Company Limited's P/E ratio?
Investors pay ₹3.5 for every ₹1 of Sun Pharma Advanced Research Company Limited's yearly profit, lower than almost all Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sun Pharma Advanced Research Company Limited: ₹5,617 Cr ÷ ₹1,339 Cr (31 Mar 2026) = 4.2.
What is Sun Pharma Advanced Research Company Limited's return on equity?
Sun Pharma Advanced Research Company Limited earned 118.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in India.
How much does Sun Pharma Advanced Research Company Limited owe compared with what it owns?
Sun Pharma Advanced Research Company Limited owes ₹0.38 for every ₹1 it owns (low), higher than 53% of Healthcare companies in India.
Does Sun Pharma Advanced Research Company Limited pay a dividend?
No. Sun Pharma Advanced Research Company Limited does not currently pay a dividend.
Is Sun Pharma Advanced Research Company Limited's revenue growing?
Revenue fell 45% in the year to Mar 2026, and shrank 45% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.